Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Indacaterol maleate
Indacaterol maleate
Indacaterol maleate
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)
Eligibility Criteria
Inclusion Criteria:
- Male and female patients 18 to 65 years old (inclusive)
- Patients with mild to moderate persistent asthma
- BMI must be within the range of 18-32 kg/m2 inclusive
Female subjects must:
- have been sterilized at least 6 months prior to screening
- be post-menopausal with no regular bleeding for at least a year prior to inclusion
Exclusion Criteria:
- Patients with life-threatening arrhythmias
- Patients with COPD or diabetes mellitus
- History of immunocompromise, including a positive HIV
- A positive Hepatitis B surface antigen (HBsAg) of Hepatitis C test result
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Novartis Investigator Site
- Novartis Investigator Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
1
2
3
4
Arm Description
Active Comparator 1 different salt formulation of Indacaterol.
Active Comparator 2 different salt formulation of Indacaterol.
Active Comparator 3 different salt formulation of Indacaterol.
Outcomes
Primary Outcome Measures
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Severity of cough: to be judged independently by both the patient and the physician
Occurrence of cough within 1 minute post dose
Number of coughs
Duration of coughing
Secondary Outcome Measures
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Severity of cough: to be judged independently by both the patient and the physician
Occurrence of cough within 1 minute post dose
Number of coughs
Duration of coughing
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00624702
Brief Title
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
Official Title
A Multi-center, Randomized, Single-dose, Double-blind, 4-way Cross-over Study to Evaluate Tolerability Following Treatment With Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Novartis
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, cough, spirometry, maleate, xinafoate, acetate, SDDPI (single dose dry powder inhaler)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
98 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Active Comparator 1 different salt formulation of Indacaterol.
Arm Title
2
Arm Type
Active Comparator
Arm Description
Active Comparator 2 different salt formulation of Indacaterol.
Arm Title
3
Arm Type
Active Comparator
Arm Description
Active Comparator 3 different salt formulation of Indacaterol.
Arm Title
4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Indacaterol maleate
Intervention Description
Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Time Frame
throughout the study
Title
Severity of cough: to be judged independently by both the patient and the physician
Time Frame
throughout the study
Title
Occurrence of cough within 1 minute post dose
Time Frame
throughout the study
Title
Number of coughs
Time Frame
throughout the study
Title
Duration of coughing
Time Frame
throughout the study
Secondary Outcome Measure Information:
Title
Presence of cough within 5 minutes post dose and the onset of cough (relative to inhalation)
Time Frame
throughout the study
Title
Severity of cough: to be judged independently by both the patient and the physician
Time Frame
throughout the study
Title
Occurrence of cough within 1 minute post dose
Time Frame
throughout the study
Title
Number of coughs
Time Frame
throughout the study
Title
Duration of coughing
Time Frame
throughout the study
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Inclusion Criteria:
Male and female patients 18 to 65 years old (inclusive)
Patients with mild to moderate persistent asthma
BMI must be within the range of 18-32 kg/m2 inclusive
Female subjects must:
have been sterilized at least 6 months prior to screening
be post-menopausal with no regular bleeding for at least a year prior to inclusion
Exclusion Criteria:
Patients with life-threatening arrhythmias
Patients with COPD or diabetes mellitus
History of immunocompromise, including a positive HIV
A positive Hepatitis B surface antigen (HBsAg) of Hepatitis C test result
Other protocol-defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis
Organizational Affiliation
Novartis investigator site
Official's Role
Principal Investigator
Facility Information:
Facility Name
Novartis Investigator Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
Novartis Investigator Site
City
Montreal
State/Province
Quebec
Country
Canada
12. IPD Sharing Statement
Links:
URL
https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=3022
Description
Results for QAB149B2102 can be found on the Novartis Clinical Trial Results Website
Learn more about this trial
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma
We'll reach out to this number within 24 hrs